5 active not recruiting. 5 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Active not recruiting 5 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Blindness: new trials by email Literature Review of Blindness trials Research Report on Blindness
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene Intravitreal Injection of Ultevursen, No intervention, will not receive any active study intervention - Retinitis Pigmentosa (RP), Usher Syndrome Type 2 | Phase 2 | Active not recruiting | Laboratoires Thea | 81 | 2024-12-11 | 2026-07-09 |
| AMX0035 in Adult Patients With Wolfram Syndrome AMX0035 - Wolfram Syndrome | Phase 2 | Active not recruiting | Amylyx Pharmaceuticals Inc. | 12 | 2023-03-03 | 2026-04-14 |
| Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA] ADVM-022 - Neovascular Age-related Macular Degeneration | Phase 2 | Active not recruiting | Adverum Biotechnologies, Inc. | 69 | 2022-08-23 | 2026-10-27 |
| A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE) sepofarsen, Sham - Leber Congenital Amaurosis 10, Blindness | Phase 2 / Phase 3 | Active not recruiting | ProQR Therapeutics | 36 | 2019-04-04 | 2022-03-17 |
| A Study to Determine the Long-Term Safety, Tolerability and Biological Activity of SAR421869 in Patients With Usher Syndrome Type 1B Blood draw for the laboratory assessment - Usher's Syndrome | Phase 2 | Active not recruiting | Sanofi | 9 | 2013-09-12 | 2026-01-13 |
Eye Abnormalities (2) · Eye Diseases (2) · Eye Diseases, Hereditary (2) · Retinal Diseases (2) · Usher Syndromes (2) · Vision Disorders (2) · Choroidal Neovascularization (1) · Leber Congenital Amaurosis (1) · Leber Congenital Amaurosis 10 (1) · Macular Degeneration (1) · Meckel Syndrome, Type 4 (1) · Neurologic Manifestations (1) · Optic Atrophy, Hereditary, Leber (1) · Retinitis Pigmentosa (1)
Nervous System Diseases (5) · Congenital Abnormalities (4) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (4) · Genetic Diseases, Inborn (4) · Neurologic Manifestations (4) · Pathological Conditions, Signs and Symptoms (4) · Sensation Disorders (4) · Signs and Symptoms (4) · Abnormalities, Multiple (3) · Deaf-Blind Disorders (3) · Deafness (3) · Ear Diseases (3) · Eye Diseases (3) · Hearing Disorders (3)
4-phenylbutyric acid (1) · Blood Specimen Collection (1) · salicylhydroxamic acid (1) · sodium phenylbutyrate and taurursodiol (1)
Adverum Biotechnologies, Inc. (1) · Amylyx Pharmaceuticals Inc. (1) · Laboratoires Thea (1) · ProQR Therapeutics (1) · Sanofi (1)
United States (5) · France (4) · United Kingdom (3) · Belgium (2) · Brazil (2) · Canada (2) · Germany (2) · Italy (2) · Netherlands (2) · Denmark (1)
Adam Turpcu, PhD (1) · Camille Bedrosian, MD (1)
2018 (1)